Curvularia Allergy Shots: When Mold Sensitization Means ENT Referral, Not SCIT
Curvularia lunata is a leading cause of Allergic Fungal Rhinosinusitis (AFRS) — a surgical disease requiring endoscopic debridement and corticosteroids, not primarily allergy shots. When a patient has Curvularia sensitization plus nasal polyps and eosinophilic mucin, the workup pivots from SCIT candidacy to ENT evaluation. No SCIT-specific RCT exists for Curvularia; Alternaria DBPC-RCT evidence (Kuna 2011, Tabar 2019) provides the family-level framework if isolated rhinitis-asthma is the clinical picture.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Curvulariais covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Curvularia Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to curvularia — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of curvularia allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of curvularia immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of curvularia extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for curvularia allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing curvularia extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription curvularia immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat curvularia allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Curvularia?
The biology, taxonomy, and clinical fingerprint of Curvularia — the foundation of how SCIT targets it.
Curvularia spores have characteristic curved phragmospore morphology and are abundant in warm humid outdoor environments and in water-damaged indoor settings.
- Scientific name
- Curvularia lunata (and C. spicifera; historically grouped with Bipolaris/Helminthosporium)
- Family
- PleosporaceaePleosporales order
- Type
- Outdoor and indoor dematiaceous saprophyte; common AFRS pathogen
- Native to
- Warm humid climates worldwide; soil and decaying vegetation in tropical through temperate regions
- Allergen proteins
- No WHO/IUIS-registered Curvularia allergens as of 2024Cross-reactivity with Alternaria via enolase, MnSOD, serine protease pan-fungal proteins (Crameri 2014)
- Particle size
- Dark curved phragmospores 18-37 x 8-14 µm
- Avoidance difficulty
- Very difficult
How Curvularia Allergy Presents
Symptoms by body system — useful for distinguishing Curvularia sensitivity from overlapping allergies and infections.
Respiratory
- Chronic nasal congestion with post-nasal drip in AFRS phenotype
- Rhinitis and sneezing on high outdoor spore-count days
- Asthma exacerbations in sensitized individuals during warm humid weather
- Persistent cough from post-nasal drip in AFRS patients with nasal polyps
Ocular
- Itchy watery eyes with outdoor mold exposure
- Conjunctival injection during high-spore outdoor periods
- Allergic shiner appearance from chronic sinus congestion in AFRS
Dermal
- Atopic dermatitis flares during warm humid high-spore periods
- Non-specific skin pruritus during peak exposure
- Rare subcutaneous phaeohyphomycosis in immunocompromised patients — outside allergy scope
Systemic
- Loss of smell (anosmia) in AFRS with extensive nasal polyposis
- Fatigue from chronic sinus obstruction and sleep disruption
- Elevated total IgE (often >1000 IU/mL) as a systemic marker in AFRS
- Headache from sinus pressure and chronic inflammation
When I see a Curvularia positive on a panel, the first thing I look for is nasal polyps on exam and eosinophilic mucin on imaging. If those are present, I am not talking about starting allergy shots — I am writing a rhinology referral. AFRS is a surgical disease first. SCIT may be considered as an adjunct after debridement, but it is not the primary management pathway.
When & Where Curvularia Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: warm humid months (June-August in temperate US; year-round in tropical regions)· Essentially year-round in tropical climates; summer-dominant in temperate regions; indoor colonization persists year-round when moisture sources are present
US Exposure Map
6 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Moderate
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Moderate
- MD:
- Low
- DE:
- Low
- AZ:
- Moderate
- NM:
- Moderate
- KS:
- Low
- AR:
- Moderate
- TN:
- Moderate
- NC:
- Moderate
- SC:
- Moderate
- OK:
- Moderate
- LA:
- High
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Moderate
What Curvularia Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Curvularia shares Pleosporaceae family-level cross-reactivity with Alternaria, Ulocladium, and Stemphylium via enolase, manganese superoxide dismutase, and serine protease pan-fungal allergens (Crameri 2014). No Curvularia-specific allergen has been WHO/IUIS registered.
Is SCIT Right for Your Curvularia Allergy?
Answer these questions to assess whether your Curvularia sensitization suggests the AFRS phenotype (ENT referral) or the isolated rhinitis-asthma phenotype (SCIT evaluation).
Do you have chronic nasal obstruction that does not fully clear with antihistamines and nasal steroids?
The Curvularia SCIT Protocol
SCIT is NOT first-line treatment when Curvularia sensitization co-occurs with the AFRS phenotype (nasal polyps, eosinophilic mucin, chronic rhinosinusitis). Endoscopic sinus surgery and corticosteroids are first-line for AFRS. For non-AFRS isolated allergic rhinitis with Curvularia sensitization, Alternaria-family mold SCIT may be considered after ENT clearance.
Weekly escalating doses of non-standardized Alternaria-based mold extract, self-administered at home through Curex with a 30-minute self-observation period and a prescribed epinephrine auto-injector on hand; the first injection from each new vial or concentration is Virtual Shot Room–supervised by the care team. For patients with AFRS who are considering SCIT as an adjunct post-surgery, ENT clearance is required first. Mold vials are separated from pollen extracts to prevent protease degradation.
Maintenance frequency is individualized by your allergist once the target dose is reached. In post-surgical AFRS patients, total IgE monitoring and symptom tracking are integrated with ENT follow-up appointments.
For AFRS patients, the SCIT discontinuation decision considers both immunotherapy duration and ENT disease control status jointly.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Curvularia SCIT
No large DBPC RCT has established SCIT efficacy for the AFRS phenotype where Curvularia is most clinically relevant. Small open-label case series have suggested some adjunctive benefit post-surgery. For non-AFRS Curvularia rhinitis-asthma, Alternaria DBPC-RCT evidence provides the family-level framework.
- Alternaria SCIT: Combined symptom-medication score reduction (family-level framework for non-AFRS phenotype)63%Kuna et al., J Allergy Clin Immunol 2011, N=111 children, DBPC-RCT
- AFRS adjunctive SCIT: Limited open-label data (post-surgical, small series)30%Bassichis et al., Otolaryngol Head Neck Surg 2001, open-label, N limited
No large DBPC RCT establishes SCIT efficacy for the AFRS phenotype where Curvularia is most relevant. For AFRS, endoscopic sinus surgery plus corticosteroids remains the primary evidence-based approach. Alternaria DBPC-RCT evidence (Kuna 2011: 63.5% combined score reduction) provides the framework for non-AFRS Curvularia rhinitis-asthma, with diminished applicability across the clinical phenotype difference.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Curvularia SCIT Side Effects
When SCIT is considered for non-AFRS Curvularia rhinitis-asthma, the side-effect profile follows standard mold SCIT parameters. Pre-treatment ENT clearance is appropriate if any sinus disease is present.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection site swelling and erythema Typical wheal-and-flare reaction; resolves within hours | Rate 30-50% | Mild |
Large local reaction (>5 cm) Mold extract proteases increase local reaction rate; dose adjustment may be needed | Rate 10-20% | Moderate |
Injection site itching Usually brief; topical antihistamine cream can help | Rate 20-40% | Mild |
Delayed local swelling Appearing 4-12 hours post-injection; self-resolving | Rate 5-15% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or conjunctivitis flare Within 30 minutes of injection | Rate 0.5-1% | Mild |
Urticaria Requires antihistamine treatment and next-visit dose adjustment | Rate 0.1-0.5% | Moderate |
Asthma exacerbation Pre-injection peak flow check required; do not inject if PEF <80% personal best | Rate 0.1-0.3% | Severe |
Anaphylaxis Epinephrine auto-injector prescribed and confirmed on hand; 30-minute self-observation after each at-home dose, with the first injection from each new vial or concentration Virtual Shot Room–supervised | Rate <0.01% | Severe |
All mold SCIT requires epinephrine on hand and a mandatory 30-minute post-injection observation period — with Curex, you self-observe at home with a prescribed epinephrine auto-injector, and the first injection from each new vial or concentration is Virtual Shot Room–supervised by the care team. For AFRS patients post-surgery who are considering adjunctive Curvularia-related SCIT, ENT and allergist coordination is essential throughout the treatment course.
SCIT vs Alternatives for Curvularia
The treatment approach for Curvularia sensitization depends critically on whether the clinical phenotype is AFRS (surgery first) or isolated rhinitis-asthma (pharmacotherapy and possibly SCIT). Management pathways differ substantially between these presentations.
| Criterion | SCIT (adjunctive, non-AFRS)Best | SLIT drops | ESS + Corticosteroids (AFRS) | Medications |
|---|---|---|---|---|
| Effectiveness | 63% for Pleosporales (Kuna 2011); limited data for AFRS phenotype | Limited mold SLIT evidence; no AFRS-specific data | Primary AFRS treatment — evidence-based (Marple 2002) | Symptomatic control; insufficient for AFRS with polyps |
| 5-yr cost | $3,500-$8,000 over 5 years | $500-$2,000/yr | $15,000-$40,000 surgical episode + ongoing | $500-$2,000/yr ongoing |
| Duration | 3-5 years | 3-5 years | Surgery plus long-term maintenance | Ongoing daily use |
| Convenience | Weekly then monthly clinic visits | Daily at-home use | Surgical procedure; ongoing monitoring | Daily pills/sprays |
| Safety | Systemic reactions <1%; 30-min obs required | Lower systemic reaction risk | Surgical risks; corticosteroid side effects | Drug side effects long-term |
| Lasting effect | Yes — tolerance may persist after treatment | Evidence not established for AFRS | AFRS recurrence common without ongoing treatment | No lasting effect |
SCIT (adjunctive, non-AFRS)Best
SLIT drops
ESS + Corticosteroids (AFRS)
Medications
For the AFRS phenotype, endoscopic sinus surgery plus corticosteroids is the primary evidence-based intervention. For isolated non-AFRS rhinitis-asthma with Curvularia sensitization, Alternaria-family SCIT offers the best immunotherapy evidence — and Curex delivers that same disease-modifying SCIT as weekly at-home self-injections with pricing confirmed in a current program quote, with allergist oversight via telehealth, a prescribed epinephrine auto-injector confirmed on hand, and Virtual Shot Room–supervised dosing for the first injection from each new vial or concentration. Discuss candidacy with your allergist given the AFRS versus non-AFRS distinction.
What Curvularia SCIT Actually Costs
Most major insurers cover mold SCIT when ordered by a board-certified allergist for allergic rhinitis. AFRS surgical management is billed through ENT CPT codes. Verify your specific allergy and surgical benefits as AFRS often requires coordinated care across allergy and ENT specialties. Curex at-home IgE testing identifies specific curvularia sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your curvularia allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Curvularia SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Allergic Fungal Rhinosinusitis is a distinct chronic rhinosinusitis subtype accounting for 5-15% of all cases of chronic rhinosinusitis with nasal polyposis. Diagnosis requires five Bent-Kuhn criteria: type I hypersensitivity (positive SPT or sIgE to the implicated fungus), nasal polyposis, characteristic CT findings (heterogeneous sinus opacification with calcium deposits), eosinophilic mucin without tissue invasion, and positive fungal culture or stain of the mucin. Curvularia is one of the most frequently implicated fungi in AFRS, alongside Bipolaris. The allergic inflammatory response to inhaled Curvularia spores drives local eosinophilic mucin accumulation in the sinuses. AFRS is fundamentally different from simple fungal infection and responds to surgery plus corticosteroids rather than antifungal therapy or SCIT alone.
Allergic Fungal Rhinosinusitis is driven by a complex local eosinophilic inflammatory response that causes eosinophilic mucin to accumulate in the sinuses, eventually forming polyps that block drainage and airflow. This process requires physical removal (endoscopic sinus surgery) because the mucin and polyp burden cannot be cleared by immunotherapy alone. Corticosteroids — both topical and occasionally systemic — are needed to suppress the eosinophilic inflammation post-surgery. SCIT has been studied as an adjunct in small open-label series (Bassichis 2001) with some benefit in reducing recurrence, but no large DBPC RCT has established it as a primary intervention. Surgery is the essential first step; immunotherapy is considered afterward.
Yes. For patients whose Curvularia sensitization presents as isolated allergic rhinitis and asthma without the AFRS phenotype (no nasal polyposis, no eosinophilic mucin on imaging), SCIT may be a reasonable consideration. The treatment uses Alternaria-based extract with the Kuna 2011 family-level DBPC-RCT evidence as the closest applicable framework, given shared Pleosporaceae cross-reactivity. A board-certified allergist will assess your full sensitization pattern, confirm co-sensitization to Alternaria via rAlt a 1 component testing, and rule out AFRS before recommending SCIT. Pre-injection ENT clearance is still appropriate if you have any chronic sinus symptoms.
Alternaria sensitization carries the most clinically serious aeroallergen risk for asthma — an adjusted OR of 189.5 for respiratory arrest (O'Hollaren 1991 NEJM) — and has robust DBPC-RCT evidence for SCIT (Kuna 2011, Tabar 2019). Curvularia sensitization is clinically important primarily for the AFRS phenotype, where total IgE is often strikingly elevated (>1000 IU/mL) and disease is driven by sinus rather than lower-airway pathology. Pure respiratory arrest risk from Curvularia sensitization is not as well characterized as for Alternaria. The two sensitizations can co-exist; in that scenario, Alternaria SCIT risk assessment applies and Curvularia AFRS workup proceeds in parallel.
Yes. Total IgE is typically markedly elevated in AFRS — often above 1000 IU/mL — making it a useful, though not definitive, discriminating marker (Schubert 2009 Med Mycol). Standard allergic rhinitis from mold sensitization typically produces total IgE elevation but not to the same extreme degree. In practice, total IgE is used both as a diagnostic support (very high levels raise AFRS suspicion) and as a treatment-response monitor post-surgery. Normalization or significant reduction in total IgE following successful ESS and corticosteroid treatment can indicate disease control. A board-certified allergist or rhinologist will use total IgE alongside CT imaging, nasal endoscopy, and fungal culture to confirm the AFRS diagnosis.
Curvularia is primarily an outdoor saprophyte that peaks in warm humid conditions and colonizes water-damaged indoor environments when moisture sources are present. Outdoor exposure reduction involves monitoring mold spore counts and limiting outdoor activities during warm humid peak periods. Indoor management is especially important: address any water intrusion or visible mold growth within 24-48 hours (EPA guidelines recommend professional remediation for areas >10 square feet), maintain indoor humidity below 50%, use HEPA air purifiers, inspect and clean HVAC systems and dehumidifiers regularly, and use bathroom exhaust fans consistently. In warm humid climates like the southeastern US where Curvularia is most prevalent, these indoor moisture controls are particularly important for sensitized patients.
Yes. Specific IgE blood testing for Curvularia (ImmunoCAP m16) can be ordered by an allergist and collected via at-home blood draw. The blood test measures IgE antibodies to Curvularia whole extract. For AFRS evaluation, an in-clinic visit with a board-certified allergist or ENT is also needed to perform skin prick testing, nasal endoscopy, and review of CT imaging — components of the AFRS diagnostic workup that cannot be completed remotely. At-home sIgE testing is a useful starting point that provides data your allergist will use in the office to complete the workup.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.